

References

1. Nagata T, Kido J, Hamasaki A, Ishida H, Wakano Y. Regulation of glycosaminoglycan synthesis by parathyroid hormone and prostaglandin E2 in cultured dental pulp cells. *J Endod* 1991; 17(12):594-7.
2. Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: a pharmacological quandary. *J Pharmacol Toxicol Methods* 2000; 43(1):31-9.
3. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. *J Rheumatol Suppl* 1997; 49:15-9.
4. Gajraj NM. The effect of cyclooxygenase-2 inhibitors on bone healing. *Reg Anesth Pain Med* 2003; 28(5):456-65.
5. Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N et al. COX-2 selective NSAID decreases bone ingrowth in vivo. *J Orthop Res* 2002; 20(6):1164-9.
6. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. *J Bone Miner Res* 2002; 17(6):963-76.
7. Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky OS, Adams DJ et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. *J Bone Miner Res* 2002; 17(8):1430-40.
8. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. *J Clin Invest* 2002; 109(11):1405-15.
9. Evans CE, Butcher C. The influence on human osteoblasts in vitro of non-steroidal anti-inflammatory drugs which act on different cyclooxygenase enzymes. *J Bone Joint Surg Br* 2004; 86(3):444-9.
10. Boyan BD, Lohmann CH, Sisk M, Liu Y, Sylvia VL, Cochran DL et al. Both cyclooxygenase-1 and cyclooxygenase-2 mediate osteoblast response to titanium surface roughness. *J Biomed Mater Res* 2001; 55(3):350-9.

11. Li L, Pettit AR, Gregory LS, Forwood MR. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. *Cytokine Growth Factor Rev* 2006; 17(3):203-16.
12. Dahners LE, Mullis BH. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. *J Am Acad Orthop Surg* 2004; 12(3):139-43.
13. Katzung BG, Furst DE. Nonsteroidal anti-inflammatory drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Katzung B.G., editor. Basic & Clinical Pharmacology. California, San Francisco: Lange Medical Books/McGraw-Hill, 2001: 578-602.
14. Wagner W., Khanna P., Furst DE. Nonsteroidal anti-inflammatory drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Katzung B.G., editor. Basic & Clinical Pharmacology. California, San Francisco: Lange Medical Books/McGraw-Hill, 2004: 576-603.
15. Chai-amnoui P, Akarasereenont P. New trend in NSAIDs therapy: Cox-2 inhibitors and clinical NSAIDs. 1 ed. Ruen-kaew Kanpim, 2000.
16. Glew R. Lipid and metabolism II: pathways of metabolism of special lipids. In: Delvin TM, editor. Text book of biochemistry with clinical correlation. New York: Wiley-Liss, 2002: 727.
17. Hutchison R. COX-2--selective NSAIDs. *Am J Nurs* 2004; 104(3):52-5.
18. Laine L. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict? *J Pain Symptom Manage* 2002; 23(4 Suppl):S5-10.
19. Laine L. Gastrointestinal effects of NSAIDs and coxibs. *J Pain Symptom Manage* 2003; 25(2 Suppl):S32-40.
20. Wagner EF, Karsenty G. Genetic control of skeletal development. *Curr Opin Genet Dev* 2001; 11(5):527-32.
21. Foegh ML, Ramwell PW. The eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes, & related Compounds. In: Katzung B.G., editor. Basic & Clinical Pharmacology. California, San Francisco: Lange Medical Books/McGraw-Hill, 2004: 298-312.
22. Einhorn TA. Do inhibitors of cyclooxygenase-2 impair bone healing? *J Bone Miner Res* 2002; 17(6):977-8.

23. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci U S A* 2002; 99(21):13926-31.
24. Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S. The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. *Inflamm Res* 2000; 49(9):460-5.
25. FDA. FDA Statement on the Halting of a Clinical Trial of the Cox-2 Inhibitor Celebrex. 12-7-2004.
26. FDA. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 4-7-2005.
27. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. *Brain Res Brain Res Rev* 2005; 48(2):352-9.
28. Pfizer. Celebrex, Insertion Sheet. Switzerland, editor. 2006.
29. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. *J Pain Symptom Manage* 2002; 23(4 Suppl):S35-S40.
30. Hinz B, Brune K. Cyclooxygenase-2--10 years later. *J Pharmacol Exp Ther* 2002; 300(2):367-75.
31. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Am J Med* 1998; 104(3A):2S-8S.
32. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. *Biochem Pharmacol* 1999; 58(6):983-90.
33. Chang JK, Chuang LY, Ho ML, Wang GJ. Effects of nonsteroidal anti-inflammatory drugs on transforming growth factor-beta expression and bioactivity in rat osteoblast-enriched culture. *Kaohsiung J Med Sci* 2003; 19(6):278-88.
34. Coetzee M, Haag M, Claassen N, Kruger MC. Stimulation of prostaglandin E2 (PGE2) production by arachidonic acid, oestrogen and parathyroid hormone in MG-63 and MC3T3-E1 osteoblast-like cells. *Prostaglandins Leukot Essent Fatty Acids* 2005; 73(6):423-30.

35. Allen HL, Wase A, Bear WT. Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. *Acta Orthop Scand* 1980; 51(4):595-600.
36. Engesaeter LB, Sudmann B, Sudmann E. Fracture healing in rats inhibited by locally administered indomethacin. *Acta Orthop Scand* 1992; 63(3):330-3.
37. Keller J, Bunger C, Andreassen TT, Bak B, Lucht U. Bone repair inhibited by indomethacin. Effects on bone metabolism and strength of rabbit osteotomies. *Acta Orthop Scand* 1987; 58(4):379-83.
38. Trancik T, Mills W, Vinson N. The effect of indomethacin, aspirin, and ibuprofen on bone ingrowth into a porous-coated implant. *Clin Orthop Relat Res* 1989; (249):113-21.
39. Dimar JR, Ante WA, Zhang YP, Glassman SD. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. *Spine* 1996; 21(16):1870-6.
40. Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. *J Orthop Res* 2003; 21(4):670-75.
41. Gurgel BC, Ribeiro FV, Silva MA, Nociti Junior FH, Sallum AW, Sallum EA et al. Selective COX-2 inhibitor reduces bone healing in bone defects. *Pesqui Odontol Bras* 2005; 19(4):312-6.
42. Murat N, Hocaoglu N, Karatosun V, Yorukoglu K, Gidener S, Gunal I. The effects of non-selective and cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats. *Med Sci Monit* 2005; 11(12):BR449-51.
43. Jee WS, Mori S, Li XJ, Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. *Bone* 1990; 11(4):253-66.
44. Suponitzky I, Weinreb M. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. *J Endocrinol* 1998; 156(1):51-7.
45. Nagai M, Suzuki Y, Ota M. Systematic assessment of bone resorption, collagen synthesis, and calcification in chick embryonic calvaria in vitro: effects of prostaglandin E2. *Bone* 1993; 14(4):655-9.

46. Reher P, Harris M, Whiteman M, Hai HK, Meghji S. Ultrasound stimulates nitric oxide and prostaglandin E2 production by human osteoblasts. *Bone* 2002; 31(1):236-41.
47. Li JG, Chang WH, Lin JC, Sun JS. Optimum intensities of ultrasound for PGE (2) secretion and growth of osteoblasts. *Ultrasound Med Biol* 2002; 28(5):683-90.
48. Nijweide PJ, Burger EH, Feyen JH. Cells of bone: proliferation, differentiation, and hormonal regulation. *Physiol Rev* 1986; 66(4):855-86.
49. Aubin JE. Advances in the osteoblast lineage. *Biochem Cell Biol* 1998; 76(6):899-910.
50. Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation. *Bone* 1995; 17(2 Suppl):77S-83S.
51. Kierzenbaum AL. Osteogenesis. In: Kierzenbaum A.L., editor. Histology and cell biology an introduction to pathology. St.Louis, Missouri: Mosby, 2002.
52. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. *J Bone Miner Res* 1999; 14(6):893-903.
53. Price PA, Baukol SA. 1, 25-Dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. *J Biol Chem* 1980; 255(24):11660-3.
54. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. *J Clin Invest* 1980; 66(5):878-83.
55. Wada Y, Kataoka H, Yokose S, Ishizuya T, Miyazono K, Gao YH et al. Changes in osteoblast phenotype during differentiation of enzymatically isolated rat calvaria cells. *Bone* 1998; 22(5):479-85.
56. Linkhart S, Mohan S, Linkhart TA, Kumegawa M, Baylink DJ. Human skeletal growth factor stimulates collagen synthesis and inhibits proliferation in a clonal osteoblast cell line (MC3T3-E1). *J Cell Physiol* 1986; 128(2):307-12.
57. Schneider G, Burrige K. Formation of focal adhesions by osteoblasts adhering to different substrata. *Exp Cell Res* 1994; 214(1):264-9.
58. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. *J Cell Biol* 1983; 96(1):191-8.

59. Franceschi RT, Iyer BS. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. *J Bone Miner Res* 1992; 7(2):235-46.
60. Kitajima I, Soejima Y, Takasaki I, Beppu H, Tokioka T, Maruyama I. Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. *Bone* 1996; 19(3):263-70.
61. Wang X, Schwartz Z, Yaffe P, Ormoy A. The expression of transforming growth factor-beta and interleukin-1beta mRNA and the response to 1,25(OH)2D3' 17 beta-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro. *Endocrine* 1999; 11(1):13-22.
62. Simon CG, Khatri CA, Wight SA, Wang FW. Preliminary report on the biocompatibility of a moldable, resorbable, composite bone graft consisting of calcium phosphate cement and poly(lactide-co-glycolide) microspheres. *Journal of Orthopaedic Research* 2002; 20(3):473-82.
63. Xu HH, Simon CG, Jr. Fast setting calcium phosphate-chitosan scaffold: mechanical properties and biocompatibility. *Biomaterials* 2005; 26(12):1337-48.
64. St-Pierre JP, Gauthier M, Lefebvre, LP, Tabriziana M. Three-dimensional growth of differentiating MC3T3-E1 pre-osteoblasts on porous titanium scaffolds. *Biomaterials* 2005; 26:7319-28.
65. Nicholson JW. Metals. The chemistry of medicals and dental materials. Bodmin, Cornwall: MPG Ltd, 2002: 107-47.
66. Okazaki Y, Rao S, Tateishi T, Ito Y. Cytocompatibility of various metals and development of new titanium alloys for medical implants. *Materials Science and Engineering A243* 1998; A243:250-6.
67. Davies JE, Lowenberg B, Shiga A. The bone-titanium interface in vitro. *J Biomed Mater Res* 1990; 24(10):1289-306.
68. Plank Jr.H, Zitter H. Material considerations. In: Georg Watzek, editor. Endosseous implants: scientific and clinical aspects. Quintessence Publishing Co, Inc, 1996: 63-96.
69. Kasemo B. Biological surface science. *Current Opinion in Solid State & Materials Science* 3, 451-9. 1998.
70. Kasemo B. Biological surface science. *Surface Science* 2002; 500:656-77.

71. Lincks J, Boyan B, Blanchard C, Loahmann C, Liu Y, Cochran DL et al. Response of MG63 osteoblast-like cells to titanium and titanium alloy is dependent on surface roughness and composition. *Biomaterials* 1998; 19:2219-32.
72. Kasemo B, Lausmaa J. Biomaterial and implant surfaces: on the role of cleanliness, contamination, and preparation procedures. *J Biomed Mater Res* 1988; 22(A2 Suppl):145-58.
73. Kasemo B, Lausmaa J. Biomaterial and implant surfaces: a surface science approach. *Int J Oral Maxillofac Implants* 1988; 3(4):247-59.
74. Cehreli M, Duyck J, De Cooman M, Puers R, Naert I. Implant design and interface force transfer. A photoelastic and strain-gauge analysis. *Clin Oral Implants Res* 2004; 15(2):249-57.
75. Anselme K. Osteoblast adhesion on biomaterials. *Biomaterials* 2000; 21(7):667-81.
76. Kasemo B, Lausmaa J. Material-tissue interfaces: the role of surface properties and processes. *Environ Health Perspect* 1994; 102 Suppl 5:41-5.
77. Rubin CT, Lanyon LE. Regulation of bone formation by applied dynamic loads. *J Bone Joint Surg Am* 1984; 66(3):397-402.
78. Rubin CT. Skeletal strain and the functional significance of bone architecture. *Calcif Tissue Int* 1984; 36 Suppl 1:S11-8.
79. Martin JY, Schwartz Z, Hummert TW, Schraub DM, Simpson J, Lankford J, Jr. et al. Effect of titanium surface roughness on proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63). *J Biomed Mater Res* 1995; 29(3):389-401.
80. Kieswetter K, Schwartz Z, Hummert TW, Cochran DL, Simpson J, Dean DD et al. Surface roughness modulates the local production of growth factors and cytokines by osteoblast-like MG-63 cells. *J Biomed Mater Res* 1996; 32(1):55-63.
81. Gurg AK. Bone Physiology for dental implantology. In: Gurg A.K., editor. Bone biology, harvesting, and grafting for dental implants: rationale and clinical application. 2004.
82. Schenk R.K. Bone Regeneration: Biologic Basis. In: Buser D., Dahlin C, Schenk R.K., editors. Guided Bone Regeneration in Implant dentistry. St Louis, MO: Quintessence Publishing Co, Inc, 1994: 49-100.

83. Francischone CE, Vasconcelos LW, Branemark PI. Osseointegration and Its benefits. In: Francischone C.E., Vasconcelos L.W., Branemark P.I., editors. Osseointegration and esthetics in single tooth rehabilitation. 1996.
84. Tenenbaum H. Biology perspectives related to osseointegration. In: Zarb G., Lekholm U., Albrektsson T., Tenenbaum H., editors. Aging, osteoporosis, and dental implants. 1996.
85. Weiss CM, Weiss A. Implant insertion and healing. In: Weiss CM, Weiss A, editors. Principle and practice of implant dentistry. St.Louis, Missouri: Mosby, 2001: 47-66.
86. Kuptniratsaikul V, Tosayanonda O, Nilganuwong S, Thamalikitkul V. The epidemiology of osteoarthritis of the knee in elderly patients living an urban area of Bangkok. *J Med Assoc Thai* 2002; 85(2):154-61.
87. El Desoky, Ehab S. Pharmacotherapy of rheumatoid arthritis: an overview. *CTR* 2001; 62(2):92-112.
88. Cutts C, LaCaze A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. *Br J Clin Pharmacol* 2002; 54(5):522-7.
89. Wikipedia contributors. COX-2 inhibitor. Wikipedia contributors, COX-2 inhibitor, editors. 2006. Wikipedia, the Free Encyclopedia.
90. Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A et al. Osteoarthritis: an overview of the disease and its treatment strategies. *Semin Arthritis Rheum* 2005; 35(1 Suppl 1):1-10.
91. Charoencholvanich K, Pongcharoen B. Oxford knee score and SF-36: translation & reliability for use with total knee arthroscopy patients in Thailand. *J Med Assoc Thai* 2005; 88(9):1194-202.
92. Rosa AL, Beloti MM. Rat bone marrow cell response to titanium and titanium alloy with different surface roughness. *Clin Oral Implants Res* 2003; 14(1):43-8.
93. Balshi TJ. Implant rehabilitation of a patient after partial mandibulectomy: a case report. *Quintessence Int* 1995; 26(7):459-63.
94. Wang JL, Lin KL, Chen JS, Lu YC, Jiann BP, Chang HT et al. Effect of celecoxib on Ca²⁺ movement and cell proliferation in human osteoblasts. *Biochem Pharmacol* 2004; 67(6):1123-30.

95. Lohmann CH, Tandy EM, Sylvia VL, Hell-Vocke AK, Cochran DL, Dean DD et al. Response of normal female human osteoblasts (NH₂Ost) to 17 β -estradiol is modulated by implant surface morphology. *J Biomed Mater Res* 2002; 62(2):204-13.
96. Cheng AS, Chan HL, Leung WK, Wong N, Johnson PJ, Sung JJ. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. *Int J Oncol* 2003; 23(1):113-9.
97. Attawia MA, Herbert KM, Uhrich KE, Langer R, Laurencin CT. Proliferation, morphology, and protein expression by osteoblasts cultured on poly(anhydride-co-imides). *J Biomed Mater Res* 1999; 48(3):322-7.
98. Ku CH, Pioletti DP, Browne M, Gregson PJ. Effect of different Ti-6Al-4V surface treatments on osteoblasts behaviour. *Biomaterials* 2002; 23(6):1447-54.
99. Rea SM, Best SM, Bonfield W. Bioactivity of ceramic-polymer composites with varied composition and surface topography. *J Mater Sci Mater Med* 2004; 15(9):997-1005.
100. Rea SM, Brooks RA, Best SM, Kokubo T, Bonfield W. Proliferation and differentiation of osteoblast-like cells on apatite-wollastonite/polyethylene composites. *Biomaterials* 2004; 25(18):4503-12.
101. Rozycki MD, Edelstein SJ. Protein extraction and solubilization. In: Bollag DM, Rozycki MD, Edelstein SJ, editors. In protein methods. John Wiley&Sons, 1996.
102. Allison JL. Osteocalcin measurement. *Ann clin biochem* 2000; 37:432-46.
103. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. *J Bone Miner Res* 1992; 7(6):683-92.
104. Shea LD, Wang D, Franceschi RT, Mooney DJ. Engineered bone development from a pre-osteoblast cell line on three-dimensional scaffolds. *Tissue Eng* 2000; 6(6):605-617.
105. Choi JY, Lee BH, Song KB, Park RW, Kim IS, Sohn KY et al. Expression patterns of bone-related proteins during osteoblastic differentiation in MC3T3-E1 cells. *J Cell Biochem* 1996; 61(4):609-18.
106. Hutchings S. Basic methods. In: Jakoby, William B., Date, editors. Cell Culture. San Diego, California: *Academic press, Inc.*, 1979: 94-109.

107. Sato G. Basic methods. In: Jakoby, William B., Date, editors. Cell Culture. San Diego, California: *Academic press, Inc.*, 1979: 94-109.
108. Sisk MA, Lohmann CH, Cochran DL, Sylvia VL, Simpson JP, Dean DD et al. Inhibition of cyclooxygenase by indomethacin modulates osteoblast response to titanium surface roughness in a time-dependent manner. *Clin Oral Implants Res* 2001; 12(1):52-61.
109. Bachle M, Kohal RJ. A systematic review of the influence of different titanium surfaces on proliferation, differentiation and protein synthesis of osteoblast-like MG63 cells. *Clin Oral Implants Res* 2004; 15(6):683-92.
110. Lumbikanonda N, Sammons R. Bone cell attachment to dental implants of different surface characteristics. *Int J Oral Maxillofac Implants* 2001; 16(5):627-36.
111. Mustafa K, Wroblewski J, Hultenby K, Lopez BS, Arvidson K. Effects of titanium surfaces blasted with TiO₂ particles on the initial attachment of cells derived from human mandibular bone. A scanning electron microscopic and histomorphometric analysis. *Clin Oral Implants Res* 2000; 11(2):116-28.
112. Mustafa K, Wennerberg A, Wroblewski J, Hultenby K, Lopez BS, Arvidson K. Determining optimal surface roughness of TiO₂ blasted titanium implant material for attachment, proliferation and differentiation of cells derived from human mandibular alveolar bone. *Clin Oral Implants Res* 2001; 12(5):515-25.
113. Mustafa K, Rubinstein J, Lopez BS, Arvidson K. Production of transforming growth factor beta1 and prostaglandin E2 by osteoblast-like cells cultured on titanium surfaces blasted with TiO₂ particles. *Clin Oral Implants Res* 2003; 14(1):50-6.
114. Bluteau G, Pilet P, Bourges X, Bilban M, Spaethe R, Daculsi G et al. The modulation of gene expression in osteoblasts by thrombin coated on biphasic calcium phosphate ceramic. *Biomaterials* 2006; 27(15):2934-43.
115. Tanaka SM, Lib J, Duncan RL, Yokota H, Burr DB, Turner CH. Effects of broad frequency vibration on cultured osteoblasts. *Journal of Biomechanics* 2003; 36:73-80.
116. Laquerriere P, Jallot E, Kilian L, Benhayoune H, Balossier G. Effects of bioactive glass particles and their ionic products on intracellular concentrations. *J Biomed Mater Res A* 2003; 65(4):441-6.

117. Stephansson SN, Byers BA, Garcia AJ. Enhanced expression of the osteoblastic phenotype on substrates that modulate fibronectin conformation and integrin receptor binding. *Biomaterials* 2002; 23:2527-34.
118. Anselme. The relative influence of the topography and chemistry of TiAl6V4 surfaces on osteoblastic cell behaviour. *Biomaterials* 2000; 21: 1567-77.
119. Cai K, Rechtenbach A, Hao J, Bossert J, Jandt KD. Polysaccharide-protein surface modification of titanium via a layer-by-layer technique: characterization and cell behaviour aspects. *Biomaterials* 2005; 26(30):5960-71.
120. Claxton NS, Fellers TJ, Davidson MW. Laser Scanning Confocal Microscopy. www.olympusfluoview.com/theory/LSCMIntro.pdf . 2006.
121. Qiu K, Zhao XJ, Wan CX, Zhao CS, Chen YW. Effect of strontium ions on the growth of ROS17/2.8 cells on porous calcium polyphosphate scaffolds. *Biomaterials* 2006; 27(8):1277-86.
122. Lee TM, Chang E, Yang CY. Attachment and proliferation of neonatal rat calvarial osteoblasts on Ti6Al4V: effect of surface chemistries of the alloy. *Biomaterials* 2004; 25(1):23-32.
123. Ramires PA, Romito A, Cosentino F, Milella E. The influence of titania/hydroxyapatite composite coatings on in vitro osteoblasts behaviour. *Biomaterials* 2001; 22(12):1467-74.
124. Xavier SP, Carvalho PS, Beloti MM, Rosa AL. Response of rat bone marrow cells to commercially pure titanium submitted to different surface treatments. *J Dent* 2003; 31(3):173-80.
125. Zhu X., Chen J., Scheideler L, Reichl R, Gerstorfer J.G. Effects of topography and composition of titanium surface oxides on osteoblast responses. *Biomaterials* 2004; 25(18): 4087-103.
126. Cook SD, Barrack RL, Dalton JE, Thomas KA, Brown TD. Effects of indomethacin on biologic fixation of porous-coated titanium implants. *J Arthroplasty* 1995; 10(3):351-8.
127. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human

- pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci U S A* 1999; 96(1):272-7.
128. Schubkegel S.R. Characterization of the role of PGE₂ receptors on resting zone chondrocytes in modulating 24,25-(OH)₂D₃-mediated osteogenic effects. *J Periodontol* 2000; 71(7):1210.
129. Cheng K, Weng W, Wang H, Zhang S. In vitro behavior of osteoblast-like cells on fluoridated hydroxyapatite coatings. *Biomaterials* 2005; 26(32):6288-95.
130. Damrongsri D, Geva S, Salvi GE, Williams RC, Limwongse V, Offenbacher S. Cyclooxygenase-2 inhibition selectively attenuates bone morphogenetic protein-6 synthesis and bone formation during guided tissue regeneration in a rat model. *Clin Oral Implants Res* 2006; 17(1):38-47.
131. Damrongsri D, Geva S, Salvi GE, Cooper LF, Limwongse V, Offenbacher S. Effects of Delta12-prostaglandin J₂ on bone regeneration and growth factor expression in rats. *Clin Oral Implants Res* 2006; 17(1):48-57.
132. Rehman Q, Sack KE. When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations. *Postgrad Med* 1999; 106(4):95-2, 105.